The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Vasten     sodium(3R,5R)-7- [(1S,2R,6S,8S,8aS)-6...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of pravastatin


Psychiatry related information on pravastatin


High impact information on pravastatin


Chemical compound and disease context of pravastatin


Biological context of pravastatin


Anatomical context of pravastatin


Associations of pravastatin with other chemical compounds


Gene context of pravastatin

  • Four groups of subjects were treated with the HMG-CoA reductase inhibitor pravastatin (Pravachol), 20 mg twice daily for 12, 24, 48 and 72 h preoperatively [25].
  • These results suggest that inhibition of de novo cholesterol synthesis by CS-514 enhanced LDL receptor function in primary cultures of rat hepatocytes and lowered LDL-cholesterol level [26].
  • Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514) [27].
  • We attempted to determine whether inhibition of microsomal HMG-CoA reductase by pravastatin sodium would yield similar values for the maximum reaction in velocity (Vmax) and the HMG-CoA reductase-pravastatin dissociation constant (Ki) when the enzyme was in the activated state compared with the control state [28].
  • Thus, CS-514 reduces atherogenic lipoproteins and apolipoprotein B, and increases HDL and apolipoprotein A-I and A-II, and appears to be a useful drug for heterozygous familial hypercholesterolemia [29].

Analytical, diagnostic and therapeutic context of pravastatin

  • We conclude that pravastatin sodium reduces total plasma cholesterol levels in this animal model, thereby leading to smaller plaques and a different plaque type [2].
  • After more than 3 procedures of LDL-apheresis without drug therapy, combination therapy with LDL-apheresis and CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase, at a dose of 10 mg twice daily was started [30].
  • METHODS: In the first experiment, rabbits were randomized to a control group (n = 7) that was fed regular rabbit chow or to a pravastatin group (n = 7) that was fed regular rabbit chow supplemented with 10 mg/kg pravastatin sodium [31].
  • Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction [32].
  • Determination of pravastatin sodium and its isomeric metabolite in human urine by HPLC with UV detection [33].


  1. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Jacobson, T.A., Chin, M.M., Curry, C.L., Miller, V., Papademetriou, V., Schlant, R.C., LaRosa, J.C. Arch. Intern. Med. (1995) [Pubmed]
  2. Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year. Harsch, M., Braesen, J.H., Niendorf, A. Atherosclerosis (1997) [Pubmed]
  3. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine. Shiomi, M., Ito, T., Watanabe, Y., Tsujita, Y., Kuroda, M., Arai, M., Fukami, M., Fukushige, J., Tamura, A. Atherosclerosis (1990) [Pubmed]
  4. Obesity: the integrated roles of environment and genetics. Speakman, J.R. J. Nutr. (2004) [Pubmed]
  5. Crystallization and preliminary X-ray diffraction analysis of cytochrome P450sca-2 from Streptomyces carbophilus involved in production of pravastatin sodium, a tissue-selective inhibitor of HMG-CoA reductase. Ito, S., Matsuoka, T., Watanabe, I., Kagasaki, T., Serizawa, N., Hata, T. Acta Crystallogr. D Biol. Crystallogr. (1999) [Pubmed]
  6. Serum leptin levels in wild and captive populations of baboons (papio): implications for the ancestral role of leptin. Banks, W.A., Phillips-Conroy, J.E., Jolly, C.J., Morley, J.E. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  7. Regulation of retinal dehydrogenases and retinoic acid synthesis by cholesterol metabolites. Huq, M.D., Tsai, N.P., Gupta, P., Wei, L.N. EMBO J. (2006) [Pubmed]
  8. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. Stenvinkel, P., Lindholm, B., Lönnqvist, F., Katzarski, K., Heimbürger, O. J. Am. Soc. Nephrol. (2000) [Pubmed]
  9. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. Bertrand, M.E., McFadden, E.P., Fruchart, J.C., Van Belle, E., Commeau, P., Grollier, G., Bassand, J.P., Machecourt, J., Cassagnes, J., Mossard, J.M., Vacheron, A., Castaigne, A., Danchin, N., Lablanche, J.M. J. Am. Coll. Cardiol. (1997) [Pubmed]
  10. Leptin concentrations in GH deficiency: the effect of GH insensitivity. Marzullo, P., Buckway, C., Pratt, K.L., Colao, A., Guevara-Aguirre, J., Rosenfeld, R.G. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  11. Interactions of leptin and thyrotropin 24-hour secretory profiles in short normal children. Ghizzoni, L., Mastorakos, G., Ziveri, M., Furlini, M., Solazzi, A., Vottero, A., Bernasconi, S. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  12. Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Matsuoka, T., Miyakoshi, S., Tanzawa, K., Nakahara, K., Hosobuchi, M., Serizawa, N. Eur. J. Biochem. (1989) [Pubmed]
  13. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Tsuda, Y., Satoh, K., Kitadai, M., Takahashi, T., Izumi, Y., Hosomi, N. Atherosclerosis (1996) [Pubmed]
  14. Biotransformation of pravastatin sodium in humans. Everett, D.W., Chando, T.J., Didonato, G.C., Singhvi, S.M., Pan, H.Y., Weinstein, S.H. Drug Metab. Dispos. (1991) [Pubmed]
  15. Leptin inhibits insulin binding in isolated rat adipocytes. Walder, K., Filippis, A., Clark, S., Zimmet, P., Collier, G.R. J. Endocrinol. (1997) [Pubmed]
  16. Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys. Malyszko, J., Urano, T., Knöfler, R., Takada, Y., Takada, A. Thromb. Res. (1996) [Pubmed]
  17. Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses. Joyce, M., Casey, R., Gang, C., Winter, D., Kelly, C.J., Bouchier-Hayes, D.J. The British journal of surgery. (2005) [Pubmed]
  18. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Kurakata, S., Kada, M., Shimada, Y., Komai, T., Nomoto, K. Immunopharmacology (1996) [Pubmed]
  19. Metabolism of pravastatin sodium in isolated rat hepatocytes. II. Structure elucidation of the metabolites by n.m.r. spectroscopy. Nakamura, T., Yoda, K., Kuwano, H., Miyaguchi, K., Muramatsu, S., Takahagi, H., Kinoshita, T. Xenobiotica (1991) [Pubmed]
  20. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Tsujita, Y., Kuroda, M., Shimada, Y., Tanzawa, K., Arai, M., Kaneko, I., Tanaka, M., Masuda, H., Tarumi, C., Watanabe, Y. Biochim. Biophys. Acta (1986) [Pubmed]
  21. Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. Kitazawa, E., Tamura, N., Iwabuchi, H., Uchiyama, M., Muramatsu, S., Takahagi, H., Tanaka, M. Biochem. Biophys. Res. Commun. (1993) [Pubmed]
  22. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Johnston, T.P., Nguyen, L.B., Chu, W.A., Shefer, S. International journal of pharmaceutics. (2001) [Pubmed]
  23. Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters. Koide, K., Hayashi, K., Horiuchi, I., Kajiyama, G. Biochim. Biophys. Acta (1989) [Pubmed]
  24. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Sterzer, P., Meintzschel, F., Rösler, A., Lanfermann, H., Steinmetz, H., Sitzer, M. Stroke (2001) [Pubmed]
  25. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Hillebrant, C.G., Axelson, M., Björkhem, I., Wang, F.H., Nyberg, B., Einarsson, C. Eur. J. Clin. Invest. (1998) [Pubmed]
  26. Effect of a new synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on cholesterol synthesis and low density lipoprotein uptake by primary cultures of rat hepatocytes. Saito, Y., Shiki, Y., Shirai, K., Yoshida, S. Arzneimittel-Forschung. (1988) [Pubmed]
  27. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Yoshino, G., Kazumi, T., Iwai, M., Matsushita, M., Matsuba, K., Uenoyama, R., Iwatani, I., Baba, S. Atherosclerosis (1989) [Pubmed]
  28. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Johnston, T.P., Palmer, W.K. Pharmacotherapy (1997) [Pubmed]
  29. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia. Mabuchi, H., Kamon, N., Fujita, H., Michishita, I., Takeda, M., Kajinami, K., Itoh, H., Wakasugi, T., Takeda, R. Metab. Clin. Exp. (1987) [Pubmed]
  30. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis. Mabuchi, H., Fujita, H., Michishita, I., Takeda, M., Kajinami, K., Koizumi, J., Takeda, R., Takegoshi, T., Wakasugi, T., Ueda, K. Atherosclerosis (1988) [Pubmed]
  31. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. Yamanouchi, D., Banno, H., Nakayama, M., Sugimoto, M., Fujita, H., Kobayashi, M., Kuwano, H., Komori, K. J. Vasc. Surg. (2005) [Pubmed]
  32. Highly sensitive and specific determination of pravastatin sodium in plasma by high-performance liquid chromatography with laser-induced fluorescence detection after immobilized antibody extraction. Dumousseaux, C., Muramatsu, S., Takasaki, W., Takahagi, H. Journal of pharmaceutical sciences. (1994) [Pubmed]
  33. Determination of pravastatin sodium and its isomeric metabolite in human urine by HPLC with UV detection. Whigan, D.B., Ivashkiv, E., Cohen, A.I. Journal of pharmaceutical and biomedical analysis. (1989) [Pubmed]
WikiGenes - Universities